Mozart Therapeutics Highlights Pre-clinical Data of KIR x ICOS CD8 Treg Modulator at Immunology 2024
Shots:
- Mozart highlighted pre-clinical results of KIR x ICOS bispecific Ab targeting CD8 regulatory T cells at Immunology 2024 under the title, ‘Pre-clinical Pharmacology and Tolerability Characterization of a Novel KIR x ICOS Targeting Bispecific CD8 Treg Modulator’
- The data demonstrated restoration of CD8 Treg function by binding inhibitory receptor KIR & costimulatory receptor ICOS along with activating & increasing CD8 Treg’s frequency & ability to destroy pathogenic CD4 T cells in a dose-dependent manner
- It further increased the ICOS signaling in CD8 Treg cells, improved survival in a highly inflammatory disease model by decreasing proinflammatory cytokines & showed favorable tolerability in humanized mice
Ref: Mozart Therapeutics | Image: Mozart Therapeutics
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
